Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
228
resultados
Última actualización
24/04/2025 [06:52:00]
Resultados 75 a 100 de 228
Resumen de: US2025090683A1
The present invention provides a conjugate comprising: (a) a cardiovascular disease (CVD)-targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or dextran, and (c) a flavonoid. The present invention also provides to a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, optionally (b) an inner shell comprising oligomeric (−)-epigallocatechin gallate (OEGCG), and optionally (c) a CVD-treating molecule encapsulated in the inner shell. The present invention further provides a method for treating a CVD by administering an effective amount of the present nanoparticle composition to a subject. The CVD-targeting ligand targets the heart tissue and delivers active ingredients to heart tissue for treating cardiovascular diseases or conditions.
Resumen de: AU2023285047A1
The invention relates to barcoded nucleic acid nanostructure delivery compositions for
Resumen de: AU2023283389A1
The invention relates to nucleic acid nanostructure delivery compositions for non-viral delivery, and methods therefor. More particularly, the invention relates to nucleic acid nanostructure delivery compositions, such as DNA origami compositions, for the delivery, for example, of small molecule therapeutics, and methods therefor.
Resumen de: CN119173498A
The present disclosure relates to novel lipids, nanoparticles comprising such lipids and their use for delivering therapeutic agents to a subject or treating and/or preventing a disease in the subject.
Resumen de: WO2023239593A1
The invention relates to a method of treating a disease or disorder in a patient in need thereof that includes providing an active pharmaceutical ingredient (API) to the patient by administering more than one split-dose of the API over a pre-determined period of time. In embodiments of the invention, the API is an mRNA encoding an antigen. The attractiveness of mRNA as a vaccine modality is supported by several advantages. As a non-infectious agent that does not require incorporation into the host's genome to confer activity along with its well-defined chemical composition, mRNA is regarded as a relatively safe vaccine modality.
Resumen de: EP4537813A1
The present invention relates to: a thermo-sensitive poly(organophosphazene) polymer loaded with a drug; a pharmaceutical composition for preventing or treating inflammatory diseases, comprising same; and the like. An injectable polymer nanoparticle hydrogel system comprising the hydrogel has a long-term anti-inflammatory effect and can slowly release a drug at a therapeutically-effective concentration, and thus can be used in the prevention and treatment of various inflammatory diseases such as osteoarthritis.
Resumen de: WO2023238137A1
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
Resumen de: WO2023244526A1
A monolithic implantable device for delivery of an antibody is provided. The implantable device comprises a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents and optionally, one or more excipients. The therapeutic agents contain an antibody and the polymer matrix contains a hydrophobic polymer. Within a time period of 35 days, the device exhibits a cumulative weight-based release ratio of the antibody of from about 20% to about 60%.
Resumen de: EP4537818A1
The present invention relates to a method for synthesizing hybrid nanoparticles comprising apolipoproteins. Specifically, the present invention relates to a method for synthesizing hybrid nanoparticles by using a swirling microvortex device, wherein the hybrid nanoparticles may include proteins that include apolipoproteins and have various functionalities. A production method according to the present invention can be used to produce small, uniform, stable nanoparticles having various physiological activities.
Resumen de: WO2023196851A1
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.
Resumen de: MX2024012161A
Ionizable cationic lipids, methods for synthesizing them, as well as intermediates useful in synthesis of these lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is a LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.
Resumen de: AU2023283348A1
The present disclosure relates to pharmaceutical compositions comprising a lipid nanoparticle (LNP), a therapeutic nucleic acid (TNA) and at least one pharmaceutically acceptable excipient, wherein the LNP comprises at least one lipid, and wherein the LNP is capable of delivering the TNA to a retinal cell. Methods of treating ocular diseases and disorders are also provided.
Resumen de: MX2021012813A
This disclosure generally relates to releasable cytokine conjugates and methods of using the same.
Resumen de: CN119822417A
本发明提供了一种多羧基配体修饰的四氧化三铁纳米粒子形成组装体的方法。先制备表面带羧基的四氧化三铁纳米粒子，然后利用表面带羧基的四氧化三铁纳米粒子在一定温度和具有较强氧化性KMnO4的试剂刺激下形成组装体。本发明一步法制备组装体的优点在于其操作简便快捷，能够在单一的步骤中高效地完成组装过程，显著缩短了制备周期，同时减少了多步骤操作可能引入的污染和误差，有利于保持产物的均一性和稳定性，非常适合于规模化生产。
Resumen de: AU2024200425A1
Abstract The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Resumen de: CN119234042A
The present disclosure relates to a polynucleotide encoding a polypeptide, the polynucleotide comprising a 5 'UTR, a coding region encoding a polypeptide, and a 3' UTR, as well as lipid nanoparticles comprising the polynucleotide. The polynucleotides and/or lipid nanoparticles of the present disclosure are capable of increasing the level and/or activity of a polypeptide by increasing the half-life and/or expression duration of a polynucleotide encoding the polypeptide. Also disclosed herein are methods of treating a disease or condition in a subject using the lipid nanoparticles of the present disclosure.
Resumen de: MX2024011181A
The present invention provides formulations comprising polypeptides and hydroxypropyl methylcellulose acetate succinate (HPMCAS) derivatives. The formulations are stable; for example, during high temperature processing and in possible low pH environments. In addition, the HPMCAS derivatives provide protection to a pH sensitive protein against acidic degradation products from aqueous hydrolysis of poly(lactic-co- glycolic acid) (PLGA) in PLGA-based delivery systems.
Resumen de: CN119032172A
The present disclosure relates to expression repressors that reduce expression of a target plurality of genes in a cell. In some embodiments, the target plurality of genes comprise CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, and IL-8. In some embodiments, the expression repressor is targeted to the E1cRE of the CXCL locus. In some embodiments, the expression repressor is targeted to the E2cRE of the CXCL locus.
Resumen de: MX2024011768A
The present invention refers to a polynucleotide delivery particle, comprising a) at least one poly(lactic-co-glycolide); b) at least one cationic surfactant; c) at least one polynucleotide; and d) optionally at least one additive; wherein the poly(lactic-co-glycolide) has a weight average molecular weight Mw of 1000 to 9500 g/mol measured via gel permeation chromatography using polystyrene standards and chloroform. Furthermore, the present invention pertains to a method of forming the polynucleotide delivery particle according to the present invention, wherein the particle is formed by a nanoprecipitation or nanoemulsion method. Moreover, the present invention refers to an oral drug delivery composition or a parenteral drug delivery composition comprising at least one polynucleotide delivery particle according to the present invention as well as their use as a medicament.
Resumen de: WO2023192956A2
Provided herein are sphingolipid-loaded nanobiologics and uses thereof e.g., in innate immune regulation and the treatment of cancer.
Resumen de: MX2024012406A
The invention relates to a three-dimensional cellular microcompartment or an assembly of three-dimensional cellular microcompartments of ovoid, cylindrical, spheroidal or spherical shape or substantially ovoid, cylindrical, spheroidal or spherical shape, the smallest dimension of which is between 200 and 400 µm, comprising an external hydrogel layer defining an internal part, said internal part having a granzyme B content of less than 1 µg/ml of medium and comprising between 500 and 5000 lymphocytes forming a three-dimensionally grouped culture. The invention also relates to a method for producing such a microcompartment or microcompartment assembly.
Resumen de: MX2024011885A
The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.
Resumen de: AU2023224888A1
Compositions, methods, and kits are provided for treating bacterial infections with nanoclusters comprising a metallic core conjugated to a nucleotide. Recalcitrant infections are often difficult to treat because of the presence of persister cells, a subpopulation of bacterial cells that is highly tolerant of traditional antibiotics. Persister cells are dormant, which makes them less susceptible to many antibiotics, which are designed to kill growing cells. Administration of nanoclusters comprising a nucleotide was found to be highly efficacious in eradicating persister cells and for treating infections for a broad range of bacterial species, including Gram-positive and Gram-negative bacteria. Such treatment was effective not only in eradicating planktonic bacteria but also bacteria in biofilms.
Resumen de: US2025011771A1
The present disclosure relates to methods, compositions and kits for modulating the expression of LPA gene and for treating lipoprotein-related diseases, for example cardiovascular diseases, in a subject by gene editing.
Nº publicación: JP2025511028A 15/04/2025
Solicitante:
ユニバーシティオブコネチカット
Resumen de: AU2023244366A1
A self-assembled nanomaterial includes a Janus base nanotube, wherein the Janus base nanotube includes at least one compound represented by Formulas I to XII, or a pharmaceutically acceptable salt thereof. Also described are compositions including the Janus base nanotubes.
BOPI
Sede Electrónica
